Senseonics Holdings, Inc.

Listed Company

SENSCIK 0001616543NasdaqNon-AcceleratedSmaller ReportingIndustrial Instruments For Measurement, Display, And ControlDelawareFY ends Dec 31

Period

FY 2025

Revenue

$35.26M

Net Income

$-69.10M

Total Assets

$126.27M

Equity

$61.05M

Shares Out

41.77M

Op. Cash Flow

$-59.13M

Business

Senseonics Holdings, Inc. develops and manufactures long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. It offers the Eversense family of implantable sensors (including Eversense E3 and Eversense 365), removable rechargeable smart transmitters, a mobile app for real-time monitoring, and related insertion and training services through its Eon Care subsidiaries. The company operates through product development and manufacturing while outsourcing global commercialization to its partner Ascensia and maintaining distributor and clinical support functions. It distributes products primarily in the United States and Europe and relies on third-party distributors, strategic fulfillment partners and direct-to-provider channels for global market access.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue, net	35	22	22	16	1
Cost of sales	19	22	19	14	14
Gross profit	16	533,000	3	3	−811,000
Research and development expenses	32	41	49	40	27
Selling, general and administrative expenses	53	34	30	32	29
Operating loss	−68	−75	−76	−69	−57
Interest income	4	5	5	2	243,000
Interest expense	−5	−8	−11	—	—
Gain on change in fair value of derivatives	—	102,000	7	184	−174
Other expense ( income)	−23,000	59,000	202,000	−102,000	−173,000
Total other expense, net	−776,000	−4	15	211	−245
Net Loss	−69	−79	−60	142	−302
Unrealized gain on marketable securities	69,000	11,000	667,000	−466,000	−212,000
Total other comprehensive income	69,000	11,000	667,000	−466,000	−212,000
Total comprehensive loss	−69	−79	−60	142	−303
Basic net loss per common share	−1.66	−2.5	−0.11	0.3	−0.72
Basic weighted-average shares outstanding	42	31	568	468	422
Diluted net loss per common share	−1.66	−2.5	−0.11	−0.11	−0.72
Diluted weighted-average shares outstanding	42	31	568	618	422

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	40	75	76	36	33
Restricted cash	315,000	315,000	—	—	—
Short term investments, net	54	—	34	108	96
Inventory, net	7	4	9	7	6
Prepaid expenses and other current assets	4	6	7	7	6
Total current assets	118	91	130	161	144
Deposits and other assets	5	5	7	3	1
Property, equipment and intangible assets, net	4	4	1	—	—
Total assets	126	100	138	178	199
Accounts payable	4	3	5	419,000	1
Accrued expenses and other current liabilities	20	16	13	15	11
Note payable, current portion, net	—	20	—	16	—
Total current liabilities	24	39	17	31	18
Long-term debt and notes payables, net	36	35	41	56	60
Non-current operating lease liabilities	5	6	6	—	—
Total liabilities	65	79	65	143	384
Commitments and contingencies	—	—	—	—	—
Preferred stock and additional paid-in-capital, subject to possible redemption: $0.001 par value per share; 0 shares and 12,000 shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	38	38	38	—
Total temporary equity	—	38	38	38	—
Common stock, $0.001 par value per share; 70,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 41,265,778 shares and 29,767,561 shares issued and outstanding as of December 31, 2025 and December 31, 2024	41,000	30,000	530,000	480,000	447,000
Additional paid-in capital	1,078	931	905	806	765
Accumulated other comprehensive income	69,000	—	−11,000	−678,000	−212,000
Accumulated deficit	−1,000	−948	−869	−809	−951
Total stockholders' equity (deficit)	61	−17	36	−3	−186
Total liabilities, temporary equity and stockholders' equity (deficit)	126	100	138	178	199

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−69	−79	−60	142	−302
Depreciation and amortization expense	2	1	1	985,000	1
Non-cash interest expense (debt discount and deferred costs)	1	4	7	12	8
Net amortization of premiums and accretion of discounts on marketable securities	−1	−1	−3	—	—
Gain on change in fair value of derivatives	—	−102,000	−7	−184	174
Stock-based compensation expense	10	9	9	9	9
Provision for inventory obsolescence and losses	694,000	4	174,000	—	—
Allowance for credit losses	931,000	220,000	—	—	—
Accounts receivable	−7	−3	−2	−478,000	1
Prepaid expenses and other current assets	1	1	162,000	−1	−2
Inventory	−3	696,000	−2	−989,000	−1
Deposits and other assets	13,000	2	−438,000	381,000	−164,000
Accounts payable	1	−2	2	−785,000	−559,000
Accrued expenses and other liabilities	5	3	−1	1	2
Accrued interest	−490,000	86,000	31,000	−95,000	372,000
Payments on lease liabilities	−939,000	−912,000	−1	—	—
Net cash used in operating activities	−59	−60	−70	−66	−56
Capital expenditures	−1	−2	−350,000	−312,000	−210,000
Purchase of marketable securities	−101	−58	−69	−105	−155
Proceeds from sale and maturity of marketable securities	48	93	159	132	6
Net cash (used in) provided by investing activities	−53	33	90	27	−149
Proceeds from exercise of stock options, RSUs and ESPP issuances, net	143,000	179,000	73,000	1	—
Proceeds from issuance of term loan, net	—	10	24	—	—
Taxes paid related to net share settlement of equity awards	−2	−2	−3	−3	−5
Repayment of 2025 Notes	−20	—	—	—	—
Proceeds from issuance of the RD Shares and the PP Warrants	—	15	—	—	—
Payment of debt modification costs	−412,000	—	—	—	—
Net cash provided by financing activities	78	27	20	42	220
Net decrease in cash and cash equivalents	−34	−797,000	40	2	15
Cash paid during the period for interest	4	5	4	7	8
Issuance of common stock converted from preferred shares	30	—	—	—	—
Property and equipment purchases included in accounts payable and accrued expenses	54,000	418,000	173,000	—	30,000
Issuance of warrants for Loan and Security Agreement	—	149,000	364,000	—	—
Change in exercise price of warrants due to Amended Loan and Security Agreement	−163,000	—	—	—	—
Acquisition of sensor insertion network assets in exchange for accounts receivable	—	725,000	—	—	—
Liabilities for contingent consideration	—	50,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro